Please use this identifier to cite or link to this item:
|Title:||Does saturable formation of gemcitabine triphosphate occur in patients?|
|Citation:||Tham, L.-S., Wang, L.-Z., Soo, R.A., Lee, H.-S., Lee, S.-C., Goh, B.-C., Holford, N.H.G. (2008-12). Does saturable formation of gemcitabine triphosphate occur in patients?. Cancer Chemotherapy and Pharmacology 63 (1) : 55-64. ScholarBank@NUS Repository. https://doi.org/10.1007/s00280-008-0707-9|
|Abstract:||Aim: This study aims to determine if intracellular formation of gemcitabine triphosphate (dFdCTP), an active metabolite of gemcitabine, is saturable at doses used for treatment of Asian patients with lung cancer. Methods: From a phase II trial, plasma concentrations of gemcitabine, its inactive metabolite 2′-2′-difluorodeoxyuridine (dFdU), and mononuclear cell concentrations of gemcitabine-triphosphate were measured in 56 and 33 patients, respectively. The pharmacokinetics of gemcitabine and metabolites were modeled using nonlinear mixed effects modeling (NONMEM). A reduced dataset of ten randomly selected patients was employed to compare first-order and saturable formation of dFdCTP from gemcitabine. Results: The median population clearance estimate for dFdCTP formation with the full dataset was 70.2 L/h/70 kg/1.7 m. Modeling Michaelis-Menten formation of dFdCTP on a reduced dataset estimated K m to be 3.6 times higher than the maximum gemcitabine concentration (72.2 μM) measured in this study. Conclusions: The results showed that first-order and nonsaturable clearance described intracellular dFdCTP formation at clinically applied doses of gemcitabine. © 2008 Springer-Verlag.|
|Source Title:||Cancer Chemotherapy and Pharmacology|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jun 15, 2018
WEB OF SCIENCETM
checked on May 15, 2018
checked on May 25, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.